Previous studies have reported that the AKT signaling pathway, downstream of FAK, can regulate cholesterol biosynthesis via SREBP-2 (33, 34), and that AKT activation is widely implicated in sorafenib resistance in HCC (35, 36). Here, SREBF2 is linked to hepatocellular carcinoma.